SCHEMBL18526151

SCHEMBL18526151

Fc1cc(Br)cnc1NCc1cccc(OC(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.47
KDM4C Q9H3R0 1/20 0.47
KDM5B Q9UGL1 1/20 0.47
USP28 Q96RU2 1/20 0.45
USP25 Q9UHP3 1/20 0.45
KCNN3 Q9UGI6 1/20 0.44
ADORA3 P0DMS8 2/20 0.43
P2RX7 Q99572 1/20 0.42
SYK P43405 1/20 0.42
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPK14 Q16539 1/20 0.41
ENPP2 Q13822 3/20 0.40
GRM2 Q14416 1/20 0.40
FLT1 P17948 1/20 0.40
KDR P35968 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18525610 0.84 KDM5A (0.52) KDM5AKDM4CKDM5BUSP28USP25
SCHEMBL18525587 0.81 KDM5A (0.49) KDM5AKDM4CKDM5BUSP28USP25
SCHEMBL18512340 0.79 CYP1A2 (0.49) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL22191205 0.78 KDM5A (0.52) KDM5AKDM4CKDM5BUSP28USP25
SCHEMBL6214100 0.77 KCNN3 (0.50) KDM5AKDM4CKDM5BUSP28USP25
SCHEMBL18526122 0.75 KDM5A (0.52) KDM5AKDM4CKDM5BSYKROCK2
SCHEMBL3277993 0.75 USP28 (0.47) KDM5AKDM4CKDM5BUSP28USP25
SCHEMBL22191066 0.75 KDM5A (0.53) KDM5AKDM4CKDM5BKCNN3P2RX7
SCHEMBL18526170 0.73 CCNT1 (0.51) KDM5AKDM4CKDM5BUSP28USP25
SCHEMBL2769633 0.73 EPHX2 (0.46) KDM5AKDM4CKDM5BKCNN3ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9783522-B2 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-10-10 US disclosed
US-20170044133-A1 NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170044133-A1 NOVEL 2-AMINO-PYRIDINE AND 2-AMINO-PYRIMIDINE DERIVATIVES AND MEDICINAL USE THEREOF ENPP2, ATXN2, ATXN2L KDM5A 1424/4885KDM4C 2216/4885KDM5B 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.